Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT-ALT: Second-line Therapies for Pneumocystis Jirovecii Pneumonia
NCT07357103Phase 4Not yet recruiting
- Sponsor
- McGill University Health Centre
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of clindamycin, primaquine, pentamidine, atovaquone in Pneumocystis jirovecii pneumonia (PJP), sponsored by McGill University Health Centre. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
clindamycinprimaquinepentamidineatovaquone
03
Conditions
Pneumocystis jirovecii pneumonia (PJP)
Beyond the preview
Go deeper on NCT07357103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357103.